Osteotech announced on 19 February, 2009 that it has received ISO 13485:2003 certification for its quality management system.
Osteotech received ISO certification for developing, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery and the processing of human bone and connective tissue for transplantation.
Osteotech’s facilities in Eatontown, New Jersey and Clermont-Ferrand, France are the processing sites for the Company’s allograft tissue grafts utilised in its broad portfolio of therapy-driven products focused on promoting regenerative and biologic healing. To date, Osteotech has successfully processed more than four million tissue grafts worldwide. The Company’s advanced technology platforms include Grafton DBM and the Plexur Biocomposite family of products as well as the DuraTech BioRegeneration Matrix, Osteotech’s leading product based upon its proprietary human collagen technology platform.